S Dawood1, N T Ueno2, V Valero2, E Andreopoulou2, L Hsu2, J Lara2, W Woodward3, T A Buchholz3, G N Hortobagyi2, M Cristofanilli2. 1. Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; Department of Medical Oncology, Dubai Hospital, Dubai, United Arab Emirates. Electronic address: ssdawood@dohms.gov.ae. 2. Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. 3. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Abstract
BACKGROUND: The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC). PATIENTS AND METHODS: Two hundred and three women with newly diagnosed stage III/IV IBC diagnosed from 2003 to 2008, with known Human epidermal growth factor receptor 2 (HER2) and hormone receptor status, were identified. Cumulative incidence of brain metastases was computed. Survival estimates were computed using the Kaplan-Meier product limit method. Multivariable Cox proportional hazards models were fitted to explore the relationship between breast tumor subtype and time to brain metastases. RESULTS: Median follow-up was 20 months. Thirty-two (15.8%) patients developed brain metastases with a cumulative incidence at 1 and 2 years of 2.7% and 18.7%, respectively. Eleven (5.3%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 1 and 2 years of 1.6% and 5.7%, respectively. Compared with women with triple receptor-negative IBC, those with hormone receptor-positive/HER2-negative disease [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.19-1.51, P = 0.24] had a decreased risk of developing brain metastases, and those with HER2-positive disease (HR = 1.02, 95% CI 0.43-2.40, P = 0.97) had an increased risk of developing brain metastases, although these associations were not statistically significant. Median survival following a diagnosis of brain metastases was 6 months. CONCLUSION: Women with newly diagnosed IBC have a high early incidence of brain metastases associated with poor survival and may be an ideal cohort to target for site-specific screening.
BACKGROUND: The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC). PATIENTS AND METHODS: Two hundred and three women with newly diagnosed stage III/IV IBC diagnosed from 2003 to 2008, with known Human epidermal growth factor receptor 2 (HER2) and hormone receptor status, were identified. Cumulative incidence of brain metastases was computed. Survival estimates were computed using the Kaplan-Meier product limit method. Multivariable Cox proportional hazards models were fitted to explore the relationship between breast tumor subtype and time to brain metastases. RESULTS: Median follow-up was 20 months. Thirty-two (15.8%) patients developed brain metastases with a cumulative incidence at 1 and 2 years of 2.7% and 18.7%, respectively. Eleven (5.3%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 1 and 2 years of 1.6% and 5.7%, respectively. Compared with women with triple receptor-negative IBC, those with hormone receptor-positive/HER2-negative disease [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.19-1.51, P = 0.24] had a decreased risk of developing brain metastases, and those with HER2-positive disease (HR = 1.02, 95% CI 0.43-2.40, P = 0.97) had an increased risk of developing brain metastases, although these associations were not statistically significant. Median survival following a diagnosis of brain metastases was 6 months. CONCLUSION:Women with newly diagnosed IBC have a high early incidence of brain metastases associated with poor survival and may be an ideal cohort to target for site-specific screening.
Authors: L Tiffany Lyle; Paul R Lockman; Chris E Adkins; Afroz Shareef Mohammad; Emily Sechrest; Emily Hua; Diane Palmieri; David J Liewehr; Seth M Steinberg; Wojciech Kloc; Ewa Izycka-Swieszewska; Renata Duchnowska; Naema Nayyar; Priscilla K Brastianos; Patricia S Steeg; Brunilde Gril Journal: Clin Cancer Res Date: 2016-05-31 Impact factor: 12.531
Authors: Maurice P H M Jansen; Leen Sas; Anieta M Sieuwerts; Caroline Van Cauwenberghe; Diana Ramirez-Ardila; Maxime Look; Kirsten Ruigrok-Ritstier; Pascal Finetti; François Bertucci; Mieke M Timmermans; Carolien H M van Deurzen; John W M Martens; Iris Simon; Paul Roepman; Sabine C Linn; Peter van Dam; Marleen Kok; Filip Lardon; Peter B Vermeulen; John A Foekens; Luc Dirix; Els M J J Berns; Steven Van Laere Journal: Mol Oncol Date: 2015-03-04 Impact factor: 6.603
Authors: Emilly S Villodre; Xiaoding Hu; Bedrich L Eckhardt; Richard Larson; Lei Huo; Ester C Yoon; Yun Gong; Juhee Song; Shuying Liu; Naoto T Ueno; Savitri Krishnamurthy; Stefan Pusch; Debu Tripathy; Wendy A Woodward; Bisrat G Debeb Journal: J Natl Cancer Inst Date: 2022-04-11 Impact factor: 11.816
Authors: Catherine L Akay; Naoto T Ueno; Gary B Chisholm; Gabriel N Hortobagyi; Wendy A Woodward; Ricardo H Alvarez; Isabelle Bedrosian; Henry M Kuerer; Kelly K Hunt; Lei Huo; Gildy V Babiera Journal: Cancer Date: 2014-02-07 Impact factor: 6.860
Authors: Weijun Wang; Haiping He; Nagore I Marín-Ramos; Shan Zeng; Steven D Swenson; Hee-Yeon Cho; Jie Fu; Paul M Beringer; Josh Neman; Ligang Chen; Axel H Schönthal; Thomas C Chen Journal: Neuro Oncol Date: 2021-10-01 Impact factor: 12.300
Authors: Allison M Martin; Daniel N Cagney; Paul J Catalano; Laura E Warren; Jennifer R Bellon; Rinaa S Punglia; Elizabeth B Claus; Eudocia Q Lee; Patrick Y Wen; Daphne A Haas-Kogan; Brian M Alexander; Nancy U Lin; Ayal A Aizer Journal: JAMA Oncol Date: 2017-08-01 Impact factor: 31.777
Authors: D J P van Uden; M C van Maaren; L J A Strobbe; P Bult; J J van der Hoeven; S Siesling; J H W de Wilt; C F J M Blanken-Peeters Journal: Breast Cancer Res Date: 2019-10-17 Impact factor: 6.466